

Table S1 Treatment interruption and dose reduction due to treatment-related adverse events (TRAEs).

| | Camrelizumab + Apatinib 125 mg (n=3) | Camrelizumab + Apatinib 250 mg (n=3) | Camrelizumab + Apatinib 375 mg (n=19) | Camrelizumab + Apatinib 500 mg (n=3) | All patients (n=28) |
|--|---|---|--|---|--------------------------------|
| Treatment interruption due to TRAEs | | | | | |
| Total | 2 (66.7) | 2 (66.7) | 10 (52.6) | 1 (33.3) | 15 (53.6) |
| Aspartate aminotransferase increased | 1 (33.3) | 1 (33.3) | 2 (10.5) | 0 | 4 (14.3) |
| Alanine aminotransferase increased | 1 (33.3) | 0 | 2 (10.5) | 0 | 3 (10.7) |
| Bilirubin conjugated increased | 2 (66.7) | 1 (33.3) | 0 | 0 | 3 (10.7) |
| Blood bilirubin increased | 2 (66.7) | 0 | 1 (5.3) | 0 | 3 (10.7) |
| Platelet count decreased | 1 (33.3) | 0 | 2 (10.5) | 0 | 3 (10.7) |
| Gamma-glutamyltransferase increased | 1 (33.3) | 0 | 1 (5.3) | 0 | 2 (7.1) |
| Blood alkaline phosphatase increased | 1 (33.3) | 0 | 1 (5.3) | 0 | 2 (7.1) |
| White blood cell count decreased | 0 | 0 | 1 (5.3) | 0 | 1 (3.6) |
| Amylase increased | 0 | 0 | 1 (5.3) | 0 | 1 (3.6) |
| Lipase increased | 0 | 0 | 1 (5.3) | 0 | 1 (3.6) |
| Proteinuria | 0 | 1 (33.3) | 1 (5.3) | 0 | 2 (7.1) |

| | | | | | |
|------------------------------------|---|---|---------|----------|---------|
| Immune-mediated hepatitis | 0 | 0 | 1 (5.3) | 0 | 1 (3.6) |
| Herpes zoster | 0 | 0 | 1 (5.3) | 0 | 1 (3.6) |
| Pneumonitis | 0 | 0 | 1 (5.3) | 0 | 1 (3.6) |
| Hypothyroidism | 0 | 0 | 1 (5.3) | 0 | 1 (3.6) |
| Rash | 0 | 0 | 0 | 1 (33.3) | 1 (3.6) |
| Pyrexia | 0 | 0 | 1 (5.3) | 0 | 1 (3.6) |
| Upper gastrointestinal hemorrhage | 0 | 0 | 1 (5.3) | 0 | 1 (3.6) |
| Hypertension | 0 | 0 | 1 (5.3) | 0 | 1 (3.6) |
| Anemia | 0 | 0 | 1 (5.3) | 0 | 1 (3.6) |
| Dose reduction due to TRAEs | | | | | |
| Total | 0 | 0 | 1 (5.3) | 0 | 1 (3.6) |
| Pain in extremity | 0 | 0 | 1 (5.3) | 0 | 1 (3.6) |

Data are shown in n (%).

Table S2 Immune-related adverse events.

| | Camrelizumab + Apatinib 125 mg (n=3) | | Camrelizumab + Apatinib 250 mg (n=3) | | Camrelizumab + Apatinib 375 mg (n=19) | | Camrelizumab + Apatinib 500 mg (n=3) | | All patients (n=28) | |
|---|--|-------------|--|-------------|---|-------------|--|-------------|---------------------|-------------|
| | Any grade | Grade ≥3 | Any grade | Grade ≥3 | Any grade | Grade ≥3 | Any grade | Grade ≥3 | Any grade | Grade ≥3 |
| Total | 0 | 0 | 3 (100) | 0 | 6 (31.6) | 2 (10.5) | 2 (66.7) | 1 (33.3) | 11 (39.3) | 3 (10.7) |
| Aspartate aminotransferase increased | 0 | 0 | 1 (33.3) | 0 | 1 (5.3) | 1 (5.3) | 0 | 0 | 2 (7.1) | 1 (3.6) |
| Hypothyroidism | 0 | 0 | 0 | 0 | 1 (5.3) | 0 | 1 (33.3) | 0 | 2 (7.1) | 0 |
| Reactive capillary endothelial proliferation | 0 | 0 | 0 | 0 | 2 (10.5) | 0 | 0 | 0 | 2 (7.1) | 0 |
| Gamma-glutamyltransferase increased | 0 | 0 | 0 | 0 | 1 (5.3) | 1 (5.3) | 0 | 0 | 1 (3.6) | 1 (3.6) |
| Alanine aminotransferase increased | 0 | 0 | 0 | 0 | 1 (5.3) | 1 (5.3) | 0 | 0 | 1 (3.6) | 1 (3.6) |
| Lymphocyte count | 0 | 0 | 0 | 0 | 1 (5.3) | 1 (5.3) | 0 | 0 | 1 (3.6) | 1 (3.6) |

| | | | | | | | | | | |
|---------------------------------------|---|---|----------|---|---------|---------|----------|----------|---------|---------|
| decreased | | | | | | | | | | |
| Blood alkaline phosphatase increased | 0 | 0 | 0 | 0 | 1 (5.3) | 0 | 0 | 0 | 1 (3.6) | 0 |
| Blood lactate dehydrogenase increased | 0 | 0 | 0 | 0 | 1 (5.3) | 0 | 0 | 0 | 1 (3.6) | 0 |
| Platelet count decreased | 0 | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 1 (3.6) | 0 |
| Immune-mediated hepatitis | 0 | 0 | 0 | 0 | 1 (5.3) | 0 | 0 | 0 | 1 (3.6) | 0 |
| Herpes zoster | 0 | 0 | 0 | 0 | 1 (5.3) | 0 | 0 | 0 | 1 (3.6) | 0 |
| Pneumonitis | 0 | 0 | 0 | 0 | 1 (5.3) | 1 (5.3) | 0 | 0 | 1 (3.6) | 1 (3.6) |
| Hyperthyroidism | 0 | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 1 (3.6) | 0 |
| Rash | 0 | 0 | 0 | 0 | 0 | 0 | 1 (33.3) | 1 (33.3) | 1 (3.6) | 1 (3.6) |
| Pyrexia | 0 | 0 | 0 | 0 | 1 (5.3) | 0 | 0 | 0 | 1 (3.6) | 0 |
| Proteinuria | 0 | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 1 (3.6) | 0 |

Data are shown in n (%).